DGFT Minutes

F. No. 01/82/0001 3/AM-24/DES-IIl/ 27 Government of India Ministry of commerce and Industry Department of commerce Directorate General of Foreign Trade (Norms Committee-lIIl)

H-Wing, Room No.414 Udyog Bhawan, New Delhi-110011 Dated +n CORRIGENDUM the 2& March, 2024 Subject: Corrigendum in respect of Case No. 251 of Minutes of Meeting No.NC/3/MEET/Dec/202324/17 dated 20.12.2023 — reg.

dated In respect of case No. 251 of Minutes of Meeting No.NC/3/MEET/Dec/20324/17 issued 20/12/2023, the following norms were fixed against following Advance Authorisation to M/s Brawn Laboratories Limited, New Delhi:

|Case No.<br>29/NC/3/MEET/Dec/20324/17<br>HQ FileNo.<br>HQRNORMAPPLY00003991AM23|Party Name:<br>Meet No. & Date:<br>Brawn<br>Laboratories |No.NC/3/MEET/Dec/20324/17<br>Limited, NewDelhi.<br>dated20/12/2023<br>RA FileNo.<br>Licence No.& Date<br>05AX04001882AM23<br>No.0511015547Dt.01/11/2022|Approved| |---|---|---|

Decision: The Committee considered the case as per agenda and it was decided to fix ad-hoc norms under Para 4.07 of HBP Vol. | as per details given below or as applied by the firm, whichever is less:-

Amikacin Qiy. allowed, 2ML(Clear colourlessSulphate toInjectionpale yellow100mgsolution| 1 Number Amikacin Sulphate | 715.81 mg filled in clear glass sealed vials.) Amikacin Sulphate Injection 500mg - | 1 Number 2 Amikacin Sulphate | 143.16 mg 2ML(Clear colourless to pale yellow solution filled in clear glass sealed vials.)

RA concerned may take further necessary action as per above decision of Norms Committee.

cin Sulphate | 143.16 mg 2ML(Clear colourless to pale yellow solution filled in clear glass sealed vials.)

RA concerned may take further necessary action as per above decision of Norms Committee.

==> picture [475 x 298] intentionally omitted <==

----- Start of picture text -----<br> 2. It is now observed that , quantity of import item mentioned at SI. No. 1 & 2 were fixed by<br>Technical Expert are inadvertently interchanged. Subsequently norms were fixed in NC-II|<br>Meeting No. NC/3/MEET/Dec/20324/17 dated 20/12/2023 and Minutes were also uploaded on<br>DGFT website.<br>3. In view of above, in consultation with Technical expert and approval of Chairman, NC-III, it<br>has been decided to correct the ad-hoc norms with respect to above Advance Authorization as<br>under:-<br>Amikacin Sulphate Injection 100mg - | 1 Number ] Amikacin Sulphate | 143.16 mg<br>2ML(Clear colourless to pale yellow solution<br>filled in clear glass sealed vials.)<br>Amikacin Sulphate Injection 500mg_ - | 1 Number 2 Amikacin Sulphate | 715.81 mg<br>2ML(Clear colourless to pale yellow solution<br>filled in clear glass sealed vials.)<br>RA concerned may take further necessary action as per above decision of NC.<br>meETOwectorSaSETor<br>Directorate gig cu Foreign Trade<br>wae of Commerce & Industry<br>Vani my Srey, eh ‘Delhi<br>----- End of picture text -----<br>